Clinical Trial Update: huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas [Phase 2]

View source ↗

Summary

This clinical trial update indicates that the Phase 2 study of huC242-DM4 for metastatic or locally advanced gastric and gastroesophageal junction cancers has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• huC242-DM4

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer | Phase 2 | Status: WITHDRAWN